These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28843617)

  • 1. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
    Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
    Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
    Noonan M; Korenblat P; Mosesova S; Scheerens H; Arron JR; Zheng Y; Putnam WS; Parsey MV; Bohen SP; Matthews JG
    J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
    Hanania NA; Noonan M; Corren J; Korenblat P; Zheng Y; Fischer SK; Cheu M; Putnam WS; Murray E; Scheerens H; Holweg CT; Maciuca R; Gray S; Doyle R; McClintock D; Olsson J; Matthews JG; Yen K
    Thorax; 2015 Aug; 70(8):748-56. PubMed ID: 26001563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
    Korenblat P; Kerwin E; Leshchenko I; Yen K; Holweg CTJ; Anzures-Cabrera J; Martin C; Putnam WS; Governale L; Olsson J; Matthews JG
    Respir Med; 2018 Jan; 134():143-149. PubMed ID: 29413502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
    Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
    Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
    Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
    Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lebrikizumab treatment in adults with asthma.
    Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
    N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
    Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
    J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
    Corren J; Szefler SJ; Sher E; Korenblat P; Soong W; Hanania NA; Berman G; Brusselle G; Zitnik R; Natalie CR; Sun L; Siu K; Wu WS; Lio P; Armstrong AW
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1215-1224.e3. PubMed ID: 38360213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
    AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
    Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
    Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.
    Yan L; Wang B; Chia YL; Roskos LK
    Clin Pharmacokinet; 2019 Jul; 58(7):943-958. PubMed ID: 30854591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma.
    Kotani N; Dolton M; Svensson RJ; Ribbing J; Friberg LE; Vadhavkar S; Cheung D; Staton T; Sperinde G; Jin J; Putnam WS; Quartino A
    J Clin Pharmacol; 2022 Jul; 62(7):905-917. PubMed ID: 34964491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma.
    Zheng Y; Abuqayyas L; Quartino A; Guan Y; Gao Y; Liu L; Hellqvist Å; Colice G; MacDonald A
    J Clin Pharmacol; 2024 Aug; 64(8):908-921. PubMed ID: 38632826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
    Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
    J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function.
    Paro-Heitor ML; Bussamra MH; Saraiva-Romanholo BM; Martins MA; Okay TS; Rodrigues JC
    Pediatr Pulmonol; 2008 Feb; 43(2):134-41. PubMed ID: 18085692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.